Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Cytori Therapeutics ($CYTX) announced the acquisition of certain assets from Azaya Therapeutics, which is a privately held firm. Under the terms of the deal, Cytori will issue $2 million in Cytori common stock up front. It will also assume nearly $2 million of Azaya’s trade payables. The deal is likely to close by the end of February.
Cytori says the deal will provide it with a proprietary liposomal nanoparticle technology which will help augmenting its position in regenerative medicine. The company stock has gained nearly 6% this year so far. However, it is still trading way below its 52 weeks high of $5.44.

Valeant Pharmaceuticals Intl Inc ($VRX) stock has made a good start this year. After its abysmal performance in 2016, the stock is up over 2 percent this year so far. Recently Allergan Inc. admitted that it had incurred disclosure violations during a hostile takeover from Valeant Pharmaceuticals. The company agreed to pay $15 million in fines and penalties.
The company is looking to boost its financial standing by selling non-core assets. The company sold its skin care brands to L’Oreal as a part of this plan. The French company paid $1.3 billion in case, as a part of the $2.12 billion sell off. Valeant has nearly $30 billion in debt.


• Synthetic Biologics ($SYN) announced that it has finalized the design of its Phase 2b/3 clinical trial assessing lead product candidate SYN-010 for the treatment of irritable bowel syndrome.
• Daiichi Sankyo ($DSKYF) announced the start of a three-part open-label Phase 1/2 study assessing U3-1402, an HER3-targeting antibody-drug conjugate, in patients with treatment-resistant HER3-positive metastatic/unresectable breast cancer.

• Synergy Pharmaceuticals ($SGYP) reported the FDA approval for plecanatide, branded as Trulance, for the treatment of adult patients with chronic ideopathic constipation.
• Allergan ($AGN) received the FDA approval for RHOFADE cream for the treatment of persistent facial redness (erythema) associated with rosacea in adults.

• Orthofix International NV ($OFIX) is reported to have agreed to pay $14M to settle charges that it paid doctors in Brazil to boost sales and improperly booked revenue.
• ViewRay ($VRAY) announced the purchase of MRIdian Linac guided radiation therapy system by the German Research Foundation.

• Biogen Inc. ($BIIB) received Hold rating from Cantor Fitzgerald. The price target for the stock has been set at $293.
• Neurocrine ($NBIX) Receives Buy rating from Needham. The price target for the stock has been set at $62.

Gainers (% price change) Last Trade Change Mkt Cap
Oclaro, Inc.
9.48 +1.35 (16.61%) 1.56B
Immunomedics, Inc.
4.46 +0.29 (6.95%) 506.52M
Omnicell, Inc.
33.95 +1.30 (3.98%) 1.24B
Cerus Corporation
4.31 +0.16 (3.86%) 441.68M
Pacira Pharmaceuticals
40.95 +1.35 (3.41%) 1.54B
Losers (% price change)
Fluidigm Corporation
6.78 -0.60 (-8.13%) 192.47M
PharmAthene, Inc.
3.15 -0.25 (-7.35%) 213.33M
Keryx Biopharmaceuticals
5.64 -0.39 (-6.47%) 598.61M
NxStage Medical, Inc.
26.30 -1.71 (-6.10%) 1.72B
Insys Therapeutics Inc
10.18 -0.65 (-6.00%) 768.22M
Most Actives (dollar volume)
Pfizer Inc.
31.70 -0.33 (-1.03%) 192.19B
UnitedHealth Group Inc
158.70 +0.96 (0.61%) 148.31B
Gilead Sciences, Inc.
71.57 -0.56 (-0.78%) 94.58B
Merck & Co., Inc.
60.33 -0.84 (-1.37%) 165.50B
Johnson & Johnson
114.20 -0.50 (-0.44%) 310.22B